Dibutyltin Disrupts Glucocorticoid Receptor Function and Impairs Glucocorticoid-induced Suppression of Cytokine Production by Christel Gumy et al.
Dibutyltin Disrupts Glucocorticoid Receptor Function and Impairs 
Glucocorticoid-induced Suppression of Cytokine Production 
 
Christel Gumy1,2, Charlie Chandsawangbhuwana3, Anna A. Dzyakanchuk1, Denise V. 
Kratschmar1, Michael E. Baker3*, and Alex Odermatt1* 
 
1Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, 
University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland 
2Department of Nephrology and Hypertension, University of Berne, Freiburgstrasse 15, CH-
3010 Berne, Switzerland 
 
3Department of Medicine, 0693 University of California, San Diego, 9500 Gilman Drive, La 
Jolla, CA 92093-0693, U.S.A. 
 
*Correspondence to: Alex Odermatt, Alex.Odermatt@unibas.ch or Michael E. Baker, 
mbaker@ucsd.edu.  
 
 
This work was supported by grants from the Swiss National Science Foundation (No 310000-
112279 and NRP50 “Endocrine Disruptors” No 4050-066575). A.O. has a Novartis Chair of 
Molecular and Systems Toxicology. 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.2
31
2.
1 
: P
os
te
d 
18
 S
ep
 2
00
8
  2
SUMMARY 
Background. Organotins are highly toxic and widely distributed environmental chemicals. 
Dibutyltin (DBT) is used as stabilizer in the production of polyvinyl chloride plastics, and it 
is also the major metabolite formed from tributyltin (TBT) in vivo. DBT is immunotoxic, 
however, the responsible targets remain to be defined. Due to the importance of 
glucocorticoids in immune-modulation, we investigated whether DBT could interfere with 
glucocorticoid receptor (GR) function. 
Methodology. We used HEK-293 cells transiently transfected with human GR as well as rat 
H4IIE hepatoma cells and native human macrophages and human THP-1 macrophages 
expressing endogenous receptor to study organotin effects on GR function. Docking of 
organotins was used to investigate the binding mechanism.   
Principal findings. We found that nanomolar concentrations of DBT, but not other organotins 
tested, inhibit ligand binding to GR and its transcriptional activity. Docking analysis 
indicated that DBT inhibits GR activation allosterically by inserting into a site close to the 
steroid-binding pocket, which disrupts a key interaction between the A-ring of the 
glucocorticoid and the GR. DBT inhibited glucocorticoid-induced expression of 
phosphoenolpyruvate carboxykinase (PEPCK) and tyrosine-aminotransferase (TAT) and 
abolished the glucocorticoid-mediated transrepression of TNF-α-induced NF-κB activity. 
Moreover, DBT abrogated the glucocorticoid-mediated suppression of interleukin-6 (IL-6) 
and TNF-α production in lipopolysaccharide (LPS)-stimulated native human macrophages 
and human THP-1 macrophages. 
Conclusions. DBT inhibits ligand binding to GR and subsequent activation of the receptor. 
By blocking GR activation, DBT may disturb metabolic functions and modulation of the 
immune system, providing an explanation for some of the toxic effects of this organotin. 
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INTRODUCTION 
Organotins are among the most toxic and widely distributed environmental 
chemicals. The most abundant organotin in the environment is tributyltin (TBT), a 
molluscicide and fungicide widely used as an antifouling paint for boat and fish nets and that 
thus is dispersed into the marine environment [1,2]. TBT interferes with reproduction in 
marine animals, inducing imposex (superimposition of male sexual characters in females) in 
gastropod molluscs, an effect used to measure TBT pollution in sea-water [3,4]. TBT 
concentrations ranging from 4-323 nM were measured in blood samples from healthy human 
subjects [5]. In mammals, organotins are hepatotoxic, neurotoxic and immunotoxic. At doses 
comparable with those found in human blood, TBT promotes Th2 cell polarization and 
exacerbates airway inflammation, providing a possible mechanism for enhanced 
susceptibility to allergic diseases [6]. Thus, TBT contamination represents a serious health 
problem and the great concern about the toxicity of TBT is underlined by recent negotiations 
of the United Nations’ International Maritime Organization for a global ban in the use of 
TBT.  
In vivo, TBT is mainly metabolized to DBT in the liver, involving cytochrome P450 
enzymes [7,8]. DBT, itself, is used in the production of polyvinyl chloride (PVC) plastic 
tubes and bottles [9], and humans are exposed to DBT by direct uptake from drinking water 
due to leaching from PVC water distribution pipes [10]. DBT is considered to be highly 
neurotoxic and immunotoxic [5,11,12], and concentrations ranging from 11-401 nM were 
measured in human blood [5]. Hence, DBT needs to be considered as a potential toxic 
chemical. Both TBT and DBT cause thymus involution by inhibiting the proliferation of 
immature CD4-/CD8+ thymocytes, but at high concentrations, they induce thymocyte 
apoptosis [13]. The immunotoxic effects of DBT are more rapid and more pronounced than 
those of TBT, raising the possibility that some effects of TBT are primarily caused by its 
metabolite DBT [14]. The target(s) for the immunotoxic actions of DBT have not been 
determined. 
We hypothesize that DBT affects one or more glucocorticoid responses because this 
steroid has important actions on the immune system [15,16]. Despite the importance of 
glucocorticoids in the regulation of immune functions, only few studies investigated the 
potential interference of environmental pollutants with glucocorticoid-mediated responses 
[17]. None of these studies investigated DBT as a disruptor of the immune response. 
With the goal of elucidating the immunotoxic mechanism of DBT and other 
organotins, we investigated their potential interference with glucocorticoid action using cells 
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expressing recombinant GR, as well as macrophages expressing endogenous GR. We found 
that DBT, in contrast to TBT, diphenyltin (DPT) and triphenyltin (TPT), inhibits 
dexamethasone binding to GR and blocks receptor activation. We then used docking software 
[18,19] to study the binding of these chemicals to the GR and provide evidence that DBT, but 
not the other organotins, disrupts an essential interaction between the A-ring on 
dexamethasone and the GR by binding to an allosteric site. 
 
RESULTS 
Dibutyltin, but not other organotins tested, inhibits the transcriptional activity of GR 
To investigate whether organotins disrupt GR-dependent transcriptional regulation, 
we employed HEK-293 cells transiently expressing recombinant human GRα and a β-
galactosidase reporter driven by a glucocorticoid-responsive MMTV-promoter. In the 
absence of organotins, 100 nM cortisol increased GR-dependent expression of galactosidase 
activity 185-fold. HEK-293 cells that were transfected only with the β-galactosidase reporter 
showed background activity because HEK-293 cells express no or very low levels of 
endogenous GR. Upon simultaneous incubation of cells with DBT and cortisol, a dose-
dependent inhibition of GR-mediated transactivation was observed (Fig. 1A). At 1 μM DBT, 
the inhibition was comparable with that of 1 μM RU486. Interestingly, the repeated 
exposure of cells to DBT increased the inhibitory effect on GR-mediated transactivation. 
Upon subjecting cells to eight changes of medium containing a given DBT concentration at 
15 min intervals and preincubation for another 14 h, a two- to three-fold stronger inhibition 
of GR transactivation was observed than in cells that were preincubated for 16 h with the 
same DBT concentration (data not shown). In contrast to DBT, a slight stimulation of 
transactivation was found for TBT, reaching a maximal effect at 250 nM (Fig. 1B). Whereas 
DPT had no effect on GR-mediated transactivation (Fig. 1C), an up to two-fold stimulation 
was observed for TPT, with a 75% increase of transactivation at 10 nM (Fig. 1D). This 
stimulation was reversed at 250-500 nM. At these concentrations, no cytotoxicity could be 
detected in the MTT assay. Dimethyltin, trimethlytin and dioctyltin, up to 1 μM, did not 
affect GR-mediated transactivation. Similar results were obtained in experiments using 10 
nM dexamethasone instead of 100 nM cortisol. None of the organotins tested stimulated GR-
mediated transactivation in the absence of glucocorticoids (data not shown). 
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Figure 1. Inhibition of GR-mediated transactivation by organotins. HEK-293 cells 
transiently expressing pMMTV-LacZ, pCMV-LUC and human GR-α were simultaneously 
incubated with 100 nM cortisol and vehicle (CTRL), various concentrations of dibutyltin 
(DBT) (A), tributyltin (TBT) (B), diphenyltin (DPT) (C), triphenyltin (TPT) (D) or 1 μM of 
RU486 (RU). After incubation for 20 h, galactosidase reporter activity, normalized to the 
internal luciferase control, was determined. Data (mean ± SD from four independent 
experiments) represent percentage relative to the control at 100 nM cortisol in the absence of 
inhibitors. *p<0.05. 
 
Dibutyltin blocks ligand binding to GR  
To assess whether DBT inhibits GR function by directly interfering with ligand 
binding, HEK-293 cells were simultaneously incubated with radiolabeled [3H]-
dexamethasone and various concentrations of DBT. A dose-dependent decrease of 
dexamethasone binding to GR was observed, with approximately 50% inhibition of binding 
upon incubation with 150 nM DBT (Fig. 2A). Addition of unlabeled dexamethasone 
revealed a typical displacement pattern of tritiated dexamethasone in the presence or absence 
of DBT (Fig. 2B,C). A more pronounced inhibitory effect by DBT on dexamethasone 
binding to GR was obtained after preincubating cells overnight with DBT-containing 
medium, with an IC50 of about 50 nM (Fig. 2C). To determine if the reduced dexamethasone 
binding to GR upon preincubation with DBT was due to decreased GR protein expression, 
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we performed Western blotting of extracts from cells expressing GR and preincubated with 
either vehicle or DBT. Incubation with DBT for either 3 h or 16 h did not alter GR 
expression relative to the actin control (Fig. 2D), suggesting that DBT did not affect the 
number of receptor complexes but decreased glucocorticoid binding affinity. Thus, 
inhibition of glucocorticoid binding to GR in the presence of DBT provides an explanation 
for the reduced transactivation of the β-galactosidase reporter.  
 
 
Figure 2. Inhibition of ligand binding to GR by dibutyltin. HEK-293 cells were 
transfected with a plasmid for human GR-α, followed by overnight incubation in serum-free 
medium containing vehicle (0.1% DMSO)(A,B) or in medium containing either vehicle or 50 
nM or 100 nM DBT (C). Cells were then incubated for 3 h with 10 nM radiolabeled 
dexamethasone and various concentrations of DBT (A) or with 10 nM radiolabeled 
dexamethasone, various concentrations of unlabeled dexamethasone and various 
concentrations of DBT (B,C) prior to removal of unbound steroids and determination of 
bound dexamethasone by scintillation counting (A). Data represent mean ± SD from three 
independent experiments. D, cells transiently expressing GR-α were preincubated for 16 h in 
serum-free medium containing vehicle (0.1 % DMSO), 10 nM dexamethasone (Dex) or 500 
nM DBT, followed by incubation for another 3 h with vehicle, 10 nM dexamethasone or 500 
nM DBT and 10 nM dexamethasone, respectively (lane 1-3). Alternatively, cells 
preincubated for 16 h in serum-free medium were incubated for 3 h in medium containing 
500 nM DBT and 10 nM dexamethasone (lane 4). Cells were lysed and the expression of GR 
protein and actin control was analyzed by Western blotting.  
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DBT disrupts glucocorticoid-dependent target gene regulation in liver cells 
The observation that DBT blocked GR activation in an overexpression cell system 
led us to test whether the disruption of GR activation could be observed in cells expressing 
endogenous receptor. Incubation of rat H4IIE hepatoma cells, a widely used liver cell model, 
with 10 nM dexamethasone for 24 h resulted in elevated PEPCK mRNA expression 
approximately 6-fold (Fig. 3A). This glucocorticoid-induced stimulation of PEPCK mRNA 
expression was diminished in a dose-dependent manner when cells were preincubated for 16 
h with DBT. The effect of glucocorticoids was almost completely abolished in the presence 
of 500 nM DBT.  
As a second marker of GR activation, we measured the effect of DBT on TAT 
activity. Incubation with 5 nM dexamethasone increased TAT activity approximately 6-fold 
in H4IIE hepatoma cells. (Fig. 3B). Treatment of cells with DBT dose-dependently 
diminished the dexamethasone-induced stimulation of TAT activity. GR antagonist RU486 
(1 μM) was used as a control. DBT had no effect on basal TAT activity in the absence of 
glucocorticoids (data not shown).  
 
Figure 3. Inhibition of glucocorticoid-mediated expression of hepatic target genes by 
dibutyltin. A, DBT prevents glucocorticoid-induced stimulation of PEPCK mRNA 
expression. H4IIE hepatoma cells were preincubated for 16 h in the absence or presence of 
DBT, followed by adding 10 nM dexamethasone and incubation for another 24 h at 37°C. 
mRNA levels were determined by real-time RT-PCR using TaqMan technology. Data (mean 
± S.D. of triplicates from four independent experiments) are relative to the ratio of PEPCK 
mRNA to β-actin control mRNA from cells treated with dexamethasone in the absence of 
DBT. B, DBT inhibits glucocorticoid-induced stimulation of TAT activity. H4IIE cells were 
preincubated for 16 h in the absence or presence of DBT, followed by adding 5 nM 
dexamethasone and incubation for another 20 h. TAT activity, determined in cell lysates and 
normalized to protein content, is given as mean ± S.D. of triplicates from four independent 
experiments and normalized to the positive control in the presence of dexamethasone. * 
p<0.05 
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DBT impairs glucocorticoid-mediated suppression of cytokine production in 
macrophages  
Exposure of macrophages to LPS strongly induces production of various pro-
inflammatory cytokines. Among them, TNF-α and IL-6 play a pivotal role in the 
inflammatory response. The anti-inflammatory effect of glucocorticoids is at least in part due 
to the modulation of cytokine-production in a GR-dependent manner. To assess potential 
interference of DBT with glucocorticoid-dependent suppression of pro-inflammatory 
cytokines, native human monocytes were differentiated into macrophages. Macrophages 
were then preincubated for 16 h with vehicle or DBT, followed by simultaneous addition of 
LPS and 10 nM dexamethasone and incubation for another 20 h. Detection by ELISA 
revealed a DBT dose-dependent abrogation of the dexamethasone-mediated suppression of 
TNF-α and IL-6 production after LPS-induced stimulation (Fig. 4A). At 500 nM the effect 
of DBT was comparable with that of 1 μM RU486. DBT alone had no effect on IL-6 or 
TNF-α production (not shown). Similar results were observed in experiments with THP-1 
cells that were differentiated into macrophages by treatment with PMA (Fig. 4B).  
 
 
 
Figure 4. Dibutyltin abrogates GR-mediated suppression of cytokine production. Native 
human monocytes (A) or THP-1 cells (B) were differentiated into macrophages, incubated 
for 16 h with various concentrations of DBT prior to the addition of LPS and 
dexamethasone. Cells were incubated for another 20 h, and the levels of TNF-α (filled bars) 
and IL-6 (open bars) were determined by ELISA. Data represent mean ± SD from three 
independent experiments, normalized to the LPS-stimulated control.   
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Dibutyltin inhibits GR-mediated trans-repression of NF-κB 
Trans-repression of NF-κB activity by GR is important for the anti-inflammatory 
action of glucocorticoids. Therefore, we tested whether DBT might reverse glucocorticoid-
dependent inhibition of NF-κB activation upon incubation with TNF-α. TNF-α strongly 
stimulated the expression of a luciferase reporter gene driven by the MHC promoter 
containing three NF-κB binding sites, an effect which was suppressed by dexamethasone 
(Fig. 5). As for the cytokine production, the glucocorticoid-mediated suppression of NF-κB 
activation was inhibited in a dose-dependent manner by DBT or by RU486.  
 
 
Figure 5. Inhibition of GR-mediated transrepression and potentiation of TNF-α-
induced activation of NF-κB. HEK-293 cells were transfected with a plasmid for a 
luciferase reporter gene under the control of a promoter containing three NF-κB binding 
sites together with a plasmid for human GR. Cells were preincubated for 16h with various 
concentrations of DBT prior to stimulation with TNF-α  in the presence of glucocorticoids. 
Data represent mean ± S.D. from three independent experiments, normalized to the TNF-α -
stimulated control.   
 
Docking of organotins into human GR 
To study the mechanism by which DBT inhibits dexamethasone binding to GR, we 
used Autodock 4 [18,19] to screen the GR 3D-structure [21] for binding sites for DBT and 
other organotins. We identified two binding sites for DBT, DPT and TPT and one site for 
TBT (Fig. 6). These are the steroid-binding site and a site that is adjacent to the steroid-
binding site [21]. Differences in the relative occupancy for each organotin in the GR are 
summarized in Table 1. The dexamethasone binding site was the primary binding site in the 
GR for all organotins. Occupancy of the steroid-binding site varied from 51% for TPT to 
100% for TBT. 
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Table 1. Relative calculated occupancy by organotins in the GR 
Organotin Dexamethasone 
pocket 
Allosteric pocket 
Dibutyltin 82% 18% 
Tributyltin 100%  
Diphenyltin 87% 13% 
Triphenyltin 56% 44% 
 
Figure 6. Docking sites for organotins in the GR. Autodock 4 was used to dock organotins 
(green) into the GR (1M2Z.pdb) (grey) without dexamethasone. DBT (A) docked into three 
sites on GR, with the highest percentage in the dexamethasone-binding site (Table 1). The 
next highest site for DBT was an adjacent allosteric pocket. Docking of TBT (B), DPT (C) 
and TPT (D) into the GR.  
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In docking each organotin into the GR, Autodock provides a summation of the van 
der Waals, hydrogen bond and desolvation energies (summation binding energy) and a 
separate calculation of the electrostatic binding energy. For organotins, the summation 
binding energy consists mainly of hydrophobic interactions. In general, the electrostatic 
binding energy is about 20% to 25% of the summation binding energy for the binding of the 
organotins into the GR. Thus, for DBT, TBT, DPT and TPT in the steroid-binding site, the 
summation binding energies are -4.8 kcal/mol, -6.2 kcal/mol, -5.4 kcal.mol and -6.4 kcal/mol, 
respectively. DBT, which is the smallest organotin has the weakest summation binding 
energy. For DBT, TBT, DPT and TPT the electrostatic binding energies are -0.9 kcal/mol, -
0.6 kcal/mol, -0.4 kcal/mol and -0.1 kcal/mol, respectively. Interestingly, DBT has the 
strongest electrostatic binding energy and TBT has the lowest electrostatic binding energy in 
the steroid-binding site. 
For DBT, DPT and TPT in the allosteric site, the summation binding energies are -4.3 
kcal/mol, -5.3 kcal/mol, -6.7 kcal/mol, respectively.  For DBT, DPT and TPT, the 
electrostatic binding energies are -1.2 kcal/mol, -1.1 kcal/mol and -1.2 kcal/mol, respectively. 
 
Organotin docking to the dexamethasone-binding site 
Figure 7A shows DBT, TBT, DPT and TPT in the dexamethasone-binding site of the 
GR derived from the structure determined by Bledsoe et al. [21]. DBT and TBT overlap the 
region where the D-ring and C17-side chain of dexamethasone insert into the GR. Both DBT 
and TBT are much smaller than dexamethasone, which reduces interactions of these 
organotins with the GR. In contrast, DPT and TPT overlap much of the dexamethasone-
binding site in the GR. In Figure 7A, we show four residues that are important in stabilizing 
binding of dexamethasone to the GR [21]. 
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Figure 7. Docking of organotins into the dexamethasone-binding site and at an 
allosteric site in the GR. A, DBT (white), TBT (blue), DPT (orange) and TPT (yellow) fit 
into the dexamethasone-binding site of the GR. In these unminimized complexes with the 
GR, DBT and TBT overlap the D-ring and DPT and TPT most of dexamethasone. Distances 
between dexamethasone and Gln570, Arg611, Asn564 and Gln642 are taken from the crystal 
structure [21]. B, organotins docked into the GR at an allosteric site close to Glu570 and 
Arg611. 
 
Organotin docking to an allosteric site 
DBT, DPT and TPT docked into the GR at an allosteric site, which is close to the A-
ring of dexamethasone (Fig. 7B). Of the four organotins that we studied, only DBT inhibits 
transcriptional activity of GR in the presence of 100 nM cortisol, which indicates that DBT 
exerts its inhibitory action by binding to the allosteric site. To investigate further the 
interaction of GR with DBT in this secondary site, we analyzed the interaction of DBT with 
GR under two conditions. First, we analyzed DBT in the apo-GR to simulate DBT binding in 
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the absence of glucocorticoids. Second, we analyzed DBT in the GR-dexamethasone 
complex. 
For the first analysis, we docked DBT into the GR and minimized the DBT-GR 
complex with Discover 3, to allow all of the amino acids in the GR to relax, so as to diminish 
unfavorable steric interactions and optimize favorable interactions between GR and DBT. 
Then, we inserted dexamethasone into the minimized structure and analyzed the interactions 
between DBT and dexamethasone with the GR. In this analysis, we focus on the effect of 
DBT on the interactions between the C3-ketone on dexamethasone and Arg611 and Gln570 in 
the GR because these amino acids have been shown to be important in stabilizing the A-ring 
of dexamethasone [21]. We also examined the interaction of Gln642 and Asn564 with 
substituents on the D ring of dexamethasone. 
Analysis of DBT in the allosteric site of the GR reveals van der Waals contacts 
between DBT and Tyr660, Tyr663, Val543, Leu544 and Arg611. There also is a coulombic 
interaction between Glu540 and tin. Importantly, as shown in Figure 8A, there are two critical 
steric clashes between dexamethasone and the GR in the minimized GR-DBT complex. First, 
Gln570 is 1.4 Å from the C3-ketone, and second, Gln642 is 1.1 Å from the C17 hydroxyl group. 
Interestingly, other key amino acids, such as Asn564, Arg611 and Phe623 [21], retain their 
favorable binding to dexamethasone. Thus, the 3D-models indicate that binding of DBT to an 
allosteric site in unliganded GR selectively distorts the ligand-binding domain and alters the 
interaction with dexamethasone. 
 
To determine if the ternary DBT-GR-dexamethasone complex could relax into a 
conformation that would be favorable for dexamethasone binding, we minimized this 
complex using Discover 3. Analysis of this complex (Fig. 8B) reveals that after energy 
minimization the steric clashes between dexamethasone and Gln570 and Gln642 have been 
removed. After minimization, Gln642 moved to have a nice hydrogen bond with the C17 
hydroxyl group, which also is present in the GR crystal structure [21]. Gln570 is more distant 
from the C3 ketone than in the crystal structure (Fig 7A). This change may be due to a van 
der Waals contact between Gln570 and DBT. Figure 8B also shows that there are changes in 
other interactions between DBT and residues in the allosteric pocket of the GR. 
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Figure 8. Interactions of dibutyltin with the GR in an allosteric site close to the 
dexamethasone-binding site. A, After minimization of the 3D-model of the DBT-GR 
complex, dexamethasone was inserted into the complex. There are steric clashes between 
dexamethasone and Gln570 and Gln642, which are absent in the GR crystal structure [21] (Fig. 
7A). The distances of Asn564, Arg611 and Phe623 to dexamethasone are similar to that in the 
GR crystal structure. B, Interaction of dexamethasone with the GR after energy minimization 
of the DBT-GR-dexamethasone complex in (A) with Discover 3. Gln570 and Gln642 have 
moved and no longer have steric clashes with dexamethasone. Asn564, however, has moved to 
4.5 Å from the C11 hydroxyl on dexamethasone. 
 
An important change, which has profound functional implications for steroid 
activation of the GR, is the loss of the contact between Asn564 and the C11 hydroxyl on 
dexamethasone. Asn564 and corresponding asparagines on the progesterone receptor (PR) and 
mineralocorticoid receptor (MR) are important in stabilizing binding and transcriptional 
activity of cognate steroids to these receptors [22]. Asn564 and Gln570 are on α-helix 3 on the 
GR, PR and MR. Arg611 is on α-helix 5. The distance between α-helix 3 and α-helix 5 is 
crucial for steroid activation of the GR, PR [22] and MR [23]. Our analysis indicates that 
DBT will alter the conformation of α-helix 3 in the GR-dexamethasone complex. 
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DISCUSSION 
Despite the fact that organotins are well known and relevant environmental 
pollutants, we are only beginning to understand their mechanisms of toxicity. An important 
advance was the recent observation that the tributyltins TBT and TPT are potent activators 
of the nuclear hormone receptors RXR and PPARγ and that they promote adipocyte 
differentiation, suggesting that these organotins might contribute to the development of 
metabolic diseases [24-27]. Interestingly, the dibutyltins DBT and DPT were found to be 
inactive toward RXR and PPARγ in these studies.  
The pathophysiological effects of DBT have been less well studied and understood. 
Here, we demonstrate for the first time that DBT at nanomolar concentrations, but not other 
organotins investigated, disrupts GR function. In a recent study we showed that the 
organotins DBT, TBT, DPT and TPT inhibited the enzyme 11β-HSD2, which catalyzes the 
conversion of active 11β-hydroxyglucocorticoids into their inactive 11-keto derivatives [28]. 
IC50 values of 11β-HSD2 inhibition between 1 μM for TPT and 5 μM for DBT were 
obtained. Thus, while some organotins such as TPT may enhance local glucocorticoid 
effects by inhibiting 11β-HSD2-dependent glucocorticoid inactivation, DBT blocks GR 
activation at concentrations that are ten-fold lower than those effective on 11β-HSD2. 
Importantly, 11β-HSD2 is not expressed in HEK-293 and H4EII cells as well as THP-1 and 
native human macrophages that are used in the present study, and the observed effects of 
DBT are not caused by altered intracellular glucocorticoid metabolism. These observations 
suggest that different organotins cause distinct disturbances of corticosteroid hormone action 
in vivo.  
The ability of DBT to inhibit GR function is relevant for human toxicity from two 
ways. First, humans are exposed to DBT through its use as a heat stabilizer in the production 
of PVC plastic materials (water distribution pipes, tubings and bottles) from which it can 
leach into drinking water [9]. And second, DBT is likely to be responsible for some of the 
toxicity of TBT in the environment, because earlier in vivo studies indicated that trialkylated 
organotins are mainly metabolized to their dialkylated forms by hepatic cytochrome P450 
enzymes through hydroxylation and dealkylation [29]. Ueno et al. showed that inhibition of 
hepatic cytochrome P450 enzymes prevented TBT-dependent hepatotoxicity [8], suggesting 
that hepatotoxicity is caused by its metabolites. DBT was hardly degraded in the liver of 
treated mice, rats and guinea pigs, indicating that the relatively inert DBT may be 
responsible for some of the TBT toxicity observed in vivo.  
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Glucocorticoids play a crucial role in the regulation of many physiological processes 
including the control of energy metabolism and the modulation of the immune system. Here, 
we demonstrate that DBT blocks the glucocorticoid-induced expression of hepatic PEPCK 
and TAT, two enzymes with a key role in energy metabolism. Furthermore, our results from 
experiments with LPS-stimulated native human macrophages and human THP-1 
macrophages show that DBT is able to abolish the suppressive effect of glucocorticoids on 
the synthesis of the pro-inflammatory cytokines TNF-α and IL-6. By reducing the GR-
dependent trans-repression of NF-κB activation, DBT disrupts the anti-inflammatory effect 
of glucocorticoids, which plays an important role for the resolution of inflammatory 
reactions.  
Our results indicate that DBT disrupts GR-mediated regulation of gene transcription 
at the initial step of receptor activation by abolishing ligand binding to the receptor. The 
effects of DBT on glucocorticoid-induced gene expression in liver cells and in macrophages 
resembled those of RU486, supporting the evidence that DBT directly inhibits GR activity. 
The concentrations of DBT that affected GR-mediated gene expression in our experiments 
were close to those found in tissue and blood samples from human and wildlife in the range 
of 3-300 nM [5,30-32]. Moreover, we observed a more pronounced effect upon 
preincubation and after repeated exposure of cells to medium containing DBT. The 
lipophilic organotin molecules have been shown to accumulate near the lipid-water interface 
of cellular membranes [33]. Thus, organotins may reach higher concentrations in tissues, 
especially in those with high lipid content, than in the circulation. A cellular accumulation is 
also consistent with studies demonstrating up to 70,000 times higher concentrations of 
organotins in plankton and other organisms compared with sea water [34]. 
The GR-dependent effects of DBT on the LPS-induced synthesis of TNF-α and IL-6 
and the subsequent activation of NF-κB found in the present study are in line with pro-
inflammatory effects of DBT and TBT previously reported [35-37]. DBT as well as TBT 
which is metabolized in vivo to DBT, induced inflammation of the bile duct associated with 
hepatic lesions [35] and acute interstitial pancreatitis [36,37]. The present study suggests that 
the exposure to DBT can interfere with glucocorticoid-mediated modulation of the immune 
system and may contribute to inflammatory diseases. DBT and other chemicals disrupting 
glucocorticoid effects might contribute, among other factors, to the high incidence of 
allergies and asthma in developed countries [38].  
Docking analysis of organotins into the GR 3D-structure revealed that DBT, TBT 
DPT and TPT dock nicely into a site overlapping the dexamethasone binding site, which 
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would be expected because these organotins are smaller than dexamethasone and should fit 
into this site. However, DBT and TBT have fewer interactions with the GR than 
dexamethasone, DPT and TBT. TBT, DPT and TPT did not inhibit GR-mediated 
transactivation, suggesting that the inhibitory actions of DBT are due to binding to an 
allosteric site. This hypothesis is supported by DBT inhibition of GR-mediated 
transcriptional activity in the presence of 100 nM cortisol, which is over ten-fold higher than 
the Kd of cortisol for GR. At this concentration, the steroid binding site on the GR will be 
occupied by cortisol. 
Docking analysis identified a binding site for DBT close to Gln570 on α-helix 3 and 
Arg611 on α-helix 5. DBT has several van der Waals contacts with residues in this allosteric 
site on the GR. Analysis of DBT in this site in the apo-GR and holo-GR reveals that DBT 
alters the interaction of dexamethasone with the GR. Analysis of the GR with DBT in the 
apo-GR revealed a conformational change in the steroid binding pocket which results in 
steric clashes between dexamethasone and Gln570 and Gln642 (Fig. 8A). Energy minimization 
of DBT in the holo-GR complex removed these steric clashes. However, after energy 
minization, Asn564 moved and lost its stabilizing contact with the C11 hydroxyl on 
dexamethasone (Fig 8B). The interaction between α-helix 3 and α-helix 5 is important in 
transcriptional activity of steroids for the GR [22]. Alteration of α-helix 3 by DBT 
occupying the allosteric site on the GR may explain how DBT inhibits dexamethasone 
binding to GR and its subsequent transcriptional activation.  
Although neither TPT nor TBT altered GR-mediated transcriptional activity in the 
absence of cortisol, both of these organotins stimulated the activity of the GR-cortisol 
complex. Binding of TPT and TBT to other proteins of the transcriptional complex or effects 
on post-translational modifications of the receptor or its associated proteins could be 
important in TBT- and TPT-induced stimulation of GR-mediated transcription in the 
presence of cortisol. 
In conclusion, the present study demonstrates that DBT, but not TBT, DPT or TPT, 
inhibits ligand binding to GR and subsequent stimulation of its transcriptional activity. 
Molecular modeling analyses indicate that binding to an allosteric site by DBT, but not by the 
other organotins, alters the orientation of key residues in the ligand binding pocket of the GR. 
Disruption of GR activation by DBT can disturb essential physiological processes such as the 
immune system, as shown by inhibition of glucocorticoid-mediated suppression of pro-
inflammatory cytokine production in macrophages. Thus, by interfering with GR function, 
DBT may contribute to immune diseases.  
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MATERIALS AND METHODS 
Analysis of transcriptional activation of reporter genes 
HEK-293 cells were cultured in Dulbecco's modified Eagle medium (DMEM), 
supplemented with 10% fetal calf serum, 4.5 g/L glucose, 50 U/mL penicillin/streptomycin, 
2 mM glutamine, and 1 mM HEPES, pH 7.4. 200,000 cells/well were seeded in poly-L-
lysine coated 24-well plates, incubated for 16 h and transfected by the calcium-phosphate 
method with plasmid for human GR-α (0.1 μg/well), MMTV-lacZ β-galactosidase reporter 
(0.15 μg/well) and pCMV-LUC luciferase transfection control (0.05 μg/well). Cells were 
washed twice with serum- and steroid-free DMEM 6 h later, followed by incubation for 16 h 
with organotins. Cortisol (100 nM) was added and cells were incubated for another 20 h. 
Cells were washed with PBS and lysed with 50 μl lysis buffer (Tropix, Applied Biosystems, 
Foster City, CA) supplemented with 0.5 mM dithiothreitol. 20 μl of lysate were analyzed for 
β-galactosidase activity using the Tropix kit and luciferase activity using a home-made 
luciferine-solution [39].  
To measure NF-κB-dependent transcriptional activity, HEK-293 cells were 
transfected with plasmid 3xMHCLUC (provided by Dr. J. Cidlowski, [40]), containing three 
binding sites for NF-κB in the promoter preceeding a luciferase gene, and a cytomegalovirus 
(CMV)-driven galactosidase control plasmid to adjust for transfection efficiency. The 
medium was exchanged by serum- and steroid-free DMEM 6 h post-transfection, and cells 
were incubated overnight with DBT. Cells were stimulated by adding 5 nM TNF-α with or 
without glucocorticoids or RU486, followed by incubation for another 24 h. Thereafter, 
luciferase and galactosidase activities were measured as described above. 
 
Glucocorticoid receptor binding assay 
HEK-293 cells (400,000 cells/well in 12-well plates) were transfected with 0.2 
μg/well GR plasmid, washed twice 6 h later with serum- and steroid-free DMEM and 
incubated in this medium overnight, followed by addition of vehicle (0.1% of methanol or 
dimethylsulfoxide) or DBT, dexamethasone and 10 nM [3H]-dexamethasone (specific 
activity 70 Ci/mmol). Alternatively, cells were preincubated overnight with vehicle or DBT 
prior to incubation with dexamethasone. After incubation with dexamethasone for 3 h, cells 
were washed three times with PBS, lysed with 300 μl of 0.4 N NaOH, and lysates were 
subjected to scintillation counting. Non-specific binding was determined in cells transfected 
with pcDNA3 control plasmid or in the presence of 1 μM RU486 and subtracted from the 
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values obtained in absence of antagonist. 
 
Glucocorticoid receptor expression analysis 
  HEK-293 cells transfected with GR plasmid were washed 6 h later with serum- and 
steroid-free medium and incubated in this medium for 16 h with vehicle control (0.1% 
DMSO), 10 nM dexamethasone or 500 nM DBT. After preincubation, cells were incubated 
for another 3 h in the presence of vehicle, 10 nM dexamethasone or 500 nM DBT and 10 nM 
dexamethasone. In a another sample, cells were preincubated overnight in serum-free 
medium, followed by incubation for 3 h with 500 nM DBT and 10 nM dexamethasone. These 
conditions were chosen according to the procedure used for GR ligand binding. GR protein 
was detected by rabbit polyclonal anti-human GR antibody at a working dilution of 1:500 
(Santa Cruz, antibody sc-1030). Actin served as a control to adjust for the amount of protein 
loaded on the SDS-gel and was detected with a rabbit polyclonal antibody. A horse-radish 
peroxidase conjugated mouse anti-rabbit antibody was used as secondary antibody for 
detection.   
 
Analysis of phosphoenolpyruvate carboxykinase (PEPCK) mRNA levels 
Rat H4EII hepatoma cells were cultured in MEM medium containing 1 mM sodium 
pyruvate and supplemented with 10% fetal calf serum, 4.5 g/L glucose, 50 U/mL 
penicillin/streptomycin, 2 mM glutamine, and 1 mM HEPES, pH 7.4. H4EII cells were 
preincubated for 16 h in serum-free MEM in the presence of various concentrations of DBT 
or vehicle (dimethylsulfoxide), followed by adding 10 nM dexamethasone and incubation 
for another 24 h at 37°C. PEPCK mRNA expression was determined by real-time RT-PCR 
as described earlier [41]. Briefly, total mRNA was extracted from H4EII cells (500’000 cells 
per well) using an mRNA isolation kit, and 100 ng of mRNA was reverse transcribed using 
SuperscriptII reverse transcriptase according to the manufacturer’s protocol (Invitrogen, 
Carlsbad CA). Relative quantification of PEPCK mRNA expression levels was performed 
on an ABI7600 Sequence Detection System (Applied Biosystems, Foster City, CA). PCR 
reactions were performed in 96 well plates using 25 ng of cDNA, TaqMan Universal PCR 
Master Mix and assay on demand primers and probes from Applied Biosystems 
(Mm01247057_g1) following the instructions from the manufacturer. The relative 
expression of each gene compared to the internal control β-actin was determined using the 2-
ΔCT method.  
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Determination of tyrosine aminotransferase (TAT) activity 
H4IIE cells (300,000 cells/well in 6-wells plate) were allowed to adhere overnight, 
and then washed twice with serum- and steroid-free MEM followed by 16 h incubation with 
DBT. Dexamethasone (5 nM) was added, and cells were incubated for another 20 h, washed 
once with PBS and lysed in lysis buffer (50 mM Tris-HCl, pH7.4, 50 mM NaCl, 0.2% 
Nonidet-P40) supplemented with Complete Mini Protease Inhibitor cocktail at a working 
dilution of 1 tablet in 25 ml (Roche Applied Science, Rotkreuz, Switzerland). After 
centrifugation (10 min, 10’000 × g, 4°C), cleared lysates were used to measure TAT activity. 
50 μl of lysate (diluted in lysis-buffer) was added to  465 μl of reaction mix (90 mM 
potassium-phosphate buffer, pH 7.4, 25 mM L-tyrosine disodium, 90 mM α-oxoglutarate, 
pH 7.0, 0.45 mM pyridoxal-5’-phosphate, pH 6.5) and incubated for 30 min at 37°C. The 
reaction was stopped by adding 35 μl 10 N KOH, and after 30 min incubation at room-
temperature, the absorbance at 331 nm against a blank (lysis buffer treated identically) was 
determined. The activity was normalized to protein content in cell lysates, as determined by 
BCA-solution (Pierce, Soccochim, Lausanne, Switzerland).   
 
Analysis of cytokine production 
THP-1 cells and native human monocytes (50,000 cells/well, 24-well plates) were 
grown in RPMI-1640 medium supplemented with 10% FCS, 50 U/ml 
penicillin/streptomycin, 2 mM glutamine and 25 mM HEPES, pH 7.4. Peripheral blood 
mononuclear cells were purified from blood of non-smoking healthy male volunteers of age 
25-40 [42]. Venous EDTA-blood (180 ml) was collected and left to sediment in 6% dextran. 
Leukocytes were enriched for monocytes using a two-step discontinuous Percoll gradient 
(1.0791 and 1.0695 g/ml). The purity of isolated monocytes was 70-80%. Native human 
monocytes were differentiated into macrophages by incubation for 7 days in culture medium 
without medium change, whereas THP-1 cells were differentiated by incubation with 5 
ng/ml PMA for 72 h. The medium was replaced by fresh RPMI-1640 containing DBT, and 
cells were incubated for 16 h. Then, 10 nM dexamethasone and 30 ng/ml LPS were added 
and cells incubated for another 20 h before harvesting the medium and analysis of IL-6 and 
TNF-α by ELISA (BD Biosciences, Allschwil, Switzerland). 
 
Docking of organotins within human GR 
The PDB files for DBT, TBT, DPT and TPT were obtained from CambridgeSoft’s 
Chemfinder chemical compound database. Human GR (PDB:1M2Z)[21] was extracted from 
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the PDB [43] and converted into an apo-monomer using a text editor. Then, organotins were 
docked into human GR using Autodock 4 [18,19]. The well depth and equilibrium separation 
for tin in DBT and other organotins were set to 0.15 kcal/mol and 4.40 Å. Initially, the grid 
size was set to cover the entire receptor. Lamarckian Genetic Algorithm (LGA) docking was 
run for 100 trials of 25 million energy evaluations each and a histogram of the binding 
energies for the various conformations was calculated [19]. This analysis identified two 
interior sites in the GR. One site overlapped the steroid-binding site. The other site was close 
to the A ring of dexamethasone. Several non-specific sites for TPT and other organotins were 
found on the surface of the GR. To analyze docking of organotins to sites with a specific 
mode of binding, we adjusted the grid to cover the interior of the GR and redid the docking as 
described above. 
The organotin-GR complex calculated by Autodock was refined with Discover 3 
software in Insight II, allowing the GR and the organotin to move to an energy minimum. 
Discover 3 was used with the ESSF force field and a distant dependent dielectric constant of 
2 for 10,000 iterations in each energy minimization. 
 
Statistical analysis 
Values are expressed as means ± SD. Data were analyzed (and significance assigned) 
using the ratio t-test in the GraphPad Prism 4 software. Data were also subjected to one- or 
two-way ANOVA using SigmaStat software (Jandel Scientific, San Rafael, CA).  
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